XML 56 R25.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Information
12 Months Ended
Dec. 31, 2024
Segment Information  
Segment Information

19.Segment Information

ASU No. 2023-07 topic 280, “Segment Reporting” establishes standards for reporting information about operating segments on a basis consistent with the Company’s internal organization structure as well as information about services categories, business segments and major customers in financial statement. The Company manages its business in one reportable operating segment, which is engaged in the manufacturing, marketing, and sales of its patented and FDA cleared product, QuantaFlo. In accordance with the “Segment Reporting” Topic 280, the Chief Executive Officer and President has been identified as the Company’s chief operating decision maker (“CODM”), who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. The CODM uses segment operating profit to allocate resources including employees, property and investments. The CODM also uses month-over-month expense variance analysis for cost control and for making decisions about allocating capital and personnel to the segment.

The following table breaks out the operations of the Company’s single reportable segment information.

December 31

December 31

    

2024

    

2023

Revenue

$

56,294

$

68,184

Less:

Cost of revenue

4,685

6,923

Research and development (1)

4,709

5,674

Sales

5,895

7,777

Sales operations

2,946

3,702

General and administration

12,651

14,208

Depreciation and amortization

283

292

Other segment expenses (2)

4,192

7,352

Segment operating profit

20,933

22,256

Interest income, net

1,877

2,471

Impairment of investments

(337)

Change in fair value of notes held for investment

128

(307)

Change in fair value of digital assets

24,933

Other corporate income (3)

13

17

Income before taxes

47,884

24,100

Income tax expense

6,985

3,517

Net income

$

40,899

$

20,583

(1)Research and development include clinical affairs and HITRUST.
(2)Other segment expenses include marketing, customer education, business development, and strategic streamlining.
(3)Other corporate income represents unallocated income.

See note 12 to the financial statements for the customers accounted for 10% or more of the revenues and receivables.

As of December 31, 2024 and 2023, all assets of the Company were located in United States of America.